[Current and future trends in gene therapy for diabetic retinopathies].
Mori
Keisuke
K
Department of Ophthalmology, Saitama Medical School.
D000256:Adenoviridae; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D003930:Diabetic Retinopathy / Q000209:etiology / Q000628:therapy*; D016503:Drug Delivery Systems; D005136:Eye Proteins / Q000008:administration & dosage* / Q000235:genetics* / Q000494:pharmacology / Q000502:physiology; D015316:Genetic Therapy / Q000379:methods / Q000639:trends*; D005822:Genetic Vectors; D006801:Humans; D008268:Macular Degeneration / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000209:etiology / Q000517:prevention & control; D009414:Nerve Growth Factors / Q000008:administration & dosage* / Q000235:genetics* / Q000494:pharmacology / Q000502:physiology; D018696:Neuroprotective Agents; D012160:Retina / Q000166:cytology; D015843:Serpins / Q000008:administration & dosage* / Q000235:genetics* / Q000494:pharmacology / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000502:physiology; D000099174:Pigment Epithelium-Derived Factor
D005136:Eye Proteins; D009414:Nerve Growth Factors; D018696:Neuroprotective Agents; D015843:Serpins; D042461:Vascular Endothelial Growth Factor A; D000099174:Pigment Epithelium-Derived Factor